Paper25756664
Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging.
Lindenberg L and 11 others. Oncotarget, 2015. Cited by 43 papers, by iCite.
Cite this record
ConductScience Library. Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging. Papers, record 25756664. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25756664
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging.
- PubMed
- Publication types
- Clinical Trial, Journal Article, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenocarcinoma | Major topic |
| Antibodies, Monoclonal | Major topic |
| GPI-Linked Proteins | Major topic |
| Lung Neoplasms | Major topic |
| Mesothelioma | Major topic |
| Pancreatic Neoplasms | Major topic |
| Radiopharmaceuticals | Major topic |
| Aged | |
| Female | |
| Humans | |
| Indium Radioisotopes | |
| Male | |
| Mesothelin | |
| Mesothelioma, Malignant | |
| Middle Aged | |
| Tomography, Emission-Computed, Single-Photon |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| Intramural NIH HHS | United States | PubMed | PubMed | ||
| ZIABC008753 | NIH | NIH RePORTER | |||
| ZIABC010816 | NIH | NIH RePORTER | |||
| ZIDBC011540 | NIH | NIH RePORTER |
References27
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10942366 | Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. | Blood | 2000 | https://conductscience.org/library/papers/10942366 | PubMed |
| 2 | 11751476 | Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). | Clin Cancer Res | 2001 | https://conductscience.org/library/papers/11751476 | PubMed |
| 3 | 14676194 | Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. | J Biol Chem | 2004 | https://conductscience.org/library/papers/14676194 | PubMed |
| 4 | 3390350 | Uptake of indium-111-labeled monoclonal antibody ZME-018 as a function of tumor size in a patient with melanoma. | Am J Physiol Imaging | 1988 | https://conductscience.org/library/papers/3390350 | PubMed |
| 5 | 1727378 | Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. | Cancer Res | 1992 | https://conductscience.org/library/papers/1727378 | PubMed |
| 6 | 1597725 | Dosimetric evaluation of immunoscintigraphy using indium-111-labeled monoclonal antibody fragments in patients with ovarian cancer. | J Nucl Med | 1992 | https://conductscience.org/library/papers/1597725 | PubMed |
| 7 | 7568060 | Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. | Proc Natl Acad Sci U S A | 1995 | https://conductscience.org/library/papers/7568060 | PubMed |
| 8 | 8542893 | The use of thallium-201 in the preoperative detection of breast cancer: an adjunct to mammography and ultrasonography. | Eur J Nucl Med | 1995 | https://conductscience.org/library/papers/8542893 | PubMed |
| 9 | 8552591 | Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. | Proc Natl Acad Sci U S A | 1996 | https://conductscience.org/library/papers/8552591 | PubMed |
| 10 | 9430477 | Pharmacokinetic modeling and absorbed dose estimation for chimeric anti-CEA antibody in humans. | J Nucl Med | 1997 | https://conductscience.org/library/papers/9430477 | PubMed |
| 11 | 15937315 | OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. | J Nucl Med | 2005 | https://conductscience.org/library/papers/15937315 | PubMed |
| 12 | 16082249 | Localization of mesothelin in epithelial ovarian cancer. | Appl Immunohistochem Mol Morphol | 2005 | https://conductscience.org/library/papers/16082249 | PubMed |
| 13 | 16428485 | Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. | Clin Cancer Res | 2006 | https://conductscience.org/library/papers/16428485 | PubMed |
| 14 | 17530026 | Novel radiolabeled antibody conjugates. | Oncogene | 2007 | https://conductscience.org/library/papers/17530026 | PubMed |
| 15 | 17940013 | Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. | Proc Natl Acad Sci U S A | 2007 | https://conductscience.org/library/papers/17940013 | PubMed |
| 16 | 18088084 | Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. | Cancer Immun | 2007 | https://conductscience.org/library/papers/18088084 | PubMed |
| 17 | 18355690 | Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003. | Nucl Med Biol | 2008 | https://conductscience.org/library/papers/18355690 | PubMed |
| 18 | 20357763 | Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. | Clin Pharmacol Ther | 2010 | https://conductscience.org/library/papers/20357763 | PubMed |
| 19 | 19744744 | Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy. | Lung Cancer | 2010 | https://conductscience.org/library/papers/19744744 | PubMed |
| 20 | 21037025 | Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. | Clin Cancer Res | 2010 | https://conductscience.org/library/papers/21037025 | PubMed |
Cited by28
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 43 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42638115 | Immuno-PET imaging of mesothelin in ovarian cancer with 68Ga-XH04: a first-in-human study. | Biomark Res | 2026 | https://conductscience.org/library/papers/42638115 | PubMed |
| 41994562 | Mesothelin biology and the evolving landscape of targeted immunotherapy. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/41994562 | PubMed |
| 41143950 | Development of a Mesothelin-Binding Engineered Scaffold Protein as a Theranostic for Pleural Mesothelioma. | Bioconjug Chem | 2025 | https://conductscience.org/library/papers/41143950 | PubMed |
| 41132647 | High mesothelin expression is associated with low cytotoxic T cell infiltration in pancreatic cancer. | Front Immunol | 2025 | https://conductscience.org/library/papers/41132647 | PubMed |
| 37388728 | Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies. | Front Immunol | 2023 | https://conductscience.org/library/papers/37388728 | PubMed |
| 37195923 | NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16/CA125 inhibitory effects. | PLoS One | 2023 | https://conductscience.org/library/papers/37195923 | PubMed |
| 35892707 | Antibody-Based Approaches to Target Pancreatic Tumours. | Antibodies (Basel) | 2022 | https://conductscience.org/library/papers/35892707 | PubMed |
| 34522250 | Mesothelin-targeted CAR-T cells for adoptive cell therapy of solid tumors. | Arch Med Sci | 2021 | https://conductscience.org/library/papers/34522250 | PubMed |
| 34439085 | Hitting the Bull's-Eye: Mesothelin's Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34439085 | PubMed |
| 34203923 | Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine? | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34203923 | PubMed |
| 33905019 | Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreatic cancer cells and enhances gemcitabine sensitivity in a xenograft mouse model. | Invest New Drugs | 2021 | https://conductscience.org/library/papers/33905019 | PubMed |
| 33418877 | Generation of a Novel Mesothelin-Targeted Oncolytic Herpes Virus and Implemented Strategies for Manufacturing. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/33418877 | PubMed |
| 32605175 | Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors. | Biomolecules | 2020 | https://conductscience.org/library/papers/32605175 | PubMed |
| 32517181 | From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32517181 | PubMed |
| 32314552 | Image-guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies. | Wiley Interdiscip Rev Nanomed Nanobiotechnol | 2020 | https://conductscience.org/library/papers/32314552 | PubMed |
| 32202104 | ImmunoPET: Concept, Design, and Applications. | Chem Rev | 2020 | https://conductscience.org/library/papers/32202104 | PubMed |
| 31463062 | Mesothelin as a biomarker for targeted therapy. | Biomark Res | 2019 | https://conductscience.org/library/papers/31463062 | PubMed |
| 30344925 | Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models. | Oncotarget | 2018 | https://conductscience.org/library/papers/30344925 | PubMed |
| 30333914 | The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model. | Oncotarget | 2018 | https://conductscience.org/library/papers/30333914 | PubMed |
| 30225616 | Translational molecular imaging in exocrine pancreatic cancer. | Eur J Nucl Med Mol Imaging | 2018 | https://conductscience.org/library/papers/30225616 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| FOLR1 | 2348 | PubTator's text mining | https://conductscience.org/library/genes/2348 | NCBI Gene |
| MSLN | 10232 | PubTator's text mining | https://conductscience.org/library/genes/10232 | NCBI Gene |
| MUC16 | 94025 | PubTator's text mining | https://conductscience.org/library/genes/94025 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25756664
GET https://conductscience.org/api/papers/v1/25756664/references?page=2